Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | TYMP | P19971 | 4/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.35 |
| ▸ | LIG3 | P49916 | 1/20 | 0.35 |
| ▸ | LIG4 | P49917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561128 | 1.00 | G6PD (0.53) | G6PDTYMPPNPCDK1CDK4 | |
| SCHEMBL12803960 | 0.71 | GPR84 (0.42) | G6PDTYMPCDK1CDK4CDK2 | |
| SCHEMBL15018449 | 0.71 | GPR84 (0.39) | G6PDTYMPPNPCDK1CDK4 | |
| SCHEMBL12265283 | 0.69 | — | — | |
| SCHEMBL4560415 | 0.69 | TYMP (0.56) | G6PDTYMPPNPMEN1KMT2A | |
| SCHEMBL1099736 | 0.69 | TYMP (0.56) | G6PDTYMPPNPMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5026974 | 0.67 | TYMP (0.58) | G6PDTYMPPNPMEN1KMT2A | |
| SCHEMBL9243616 | 0.65 | TYMP (0.52) | G6PDTYMPPNPMEN1KMT2A | |
| SCHEMBL1228773 | 0.65 | TYMP (1.00) | G6PDTYMPPNPMEN1KMT2A | |
| SCHEMBL2236804 | 0.65 | TYMP (0.52) | G6PDTYMPPNPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9040652-A | — | — | None | — | — | JP | disclosed |
| JP-3200787-A | — | — | None | — | — | JP | disclosed |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4015511-A1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | CARNEGIE MELLON UNIVERSITY (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11330999-B2 | Hyperpolarized and deuterium exchanged hyperpolarized13C and 15N-labeled xanthine, arginine, glutamine, and urea probes | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200260983-A1 | HYPERPOLARIZED AND DEUTERIUM EXCHANGED HYPERPOLARIZED13C AND 15N-LABELED XANTHINE, ARGININE, GLUTAMINE, AND UREA PROBES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-08-20 | — | — | US | disclosed |
| US-4816458-A | TOPICAL ADMINISTERING | SCHERING CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0304004-A1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1989-02-22 | — | — | EP | disclosed |
| US-4769377-A | Adenosine receptor antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0221996-A1 | SUBSTITUTED 2,3-DIHYDRO-6-HYDROXY-PYRIMIDO [2,1-f] PURINE-4,8(1H,9H)-DIONES. | SCHERING CORP (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0107165-B1 | SUBSTITUTED 9H-8-OXO-PYRIMIDO(2,1-F)PURINE-2,4-DIONES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1987-04-15 | — | — | EP | disclosed |
| WO-1986006724-A1 | SUBSTITUTED 2,3-DIHYDRO-6-HYDROXY-PYRIMIDO AD2,1-f BD-PURINE-4,8(1H,9H)-DIONES | SCHERING CORPORATION (US) | 1986-11-20 | — | — | WO | disclosed |
| US-4593095-A | ADENOSINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4569936-A | Anti-inflammatory substituted 9H-8-oxo-pyrimido[2,1-f]purine-2,4-diones | SCHERING CORPORATION (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0107165-A1 | Substituted 9H-8-oxo-pyrimido(2,1-f)purine-2,4-diones, process for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4247693-A | Process for preparing 2,4,5,6-tetraaminopyrimidine sulfate | AMERICAN CYANAMID COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200260983-A1 | HYPERPOLARIZED AND DEUTERIUM EXCHANGED HYPERPOLARIZED13C AND 15N-LABELED XANTHINE, ARGININE, GLUTAMINE, AND UREA PROBES | GLS, ARG2, ARG1 | G6PD 307/4885TYMP 933/4885PNP 160/4885 |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | G6PD 638/4885TYMP 11/4885PNP 15/4885 |
| US-11330999-B2 | Hyperpolarized and deuterium exchanged hyperpolarized13C and 15N-labeled xanthine, arginine, glutamine, and urea probes | GLS, ARG2, ARG1 | G6PD 307/4885TYMP 933/4885PNP 160/4885 |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | G6PD 1623/4885TYMP 4040/4885PNP 1590/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | G6PD 594/4885TYMP 12/4885PNP 20/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | G6PD 612/4885TYMP 241/4885PNP 190/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | G6PD 612/4885TYMP 241/4885PNP 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.